BioDuro, a research and CDMO group, opened a new peptide synthesis manufacturing facility at its campus in the Zhangjiang tech center in Shanghai.
The facility expands the company’s peptide synthesis capabilities in order to meet growing demand for products that use a variety of peptide molecules including linear peptides, cyclic peptides and various peptide-drug conjugates, it said in a Jan. 9 press release.
Financial and square footage details of the project weren’t disclosed.
BioDuro’s new facility features a kilogram-scale peptide laboratory with automated solid-phase peptide synthesizers, cleavage systems and freeze-drying equipment, supporting peptide synthesis scale-up to 800 millimole.
“Demand for peptide based programs has increased considerably, and the opening of this new laboratory provides BioDuro's customers with a significant step forward in addressing the capabilities required to scale their candidates to compete in this fast-growing field,” Armin Spura, Ph.D., BioDuro’s chief executive, said in the release.
BioDuro, which was formed in 2005 in San Diego and China originally as a CRO, merged with contract manufacturer Formex in late 2015 just months after being acquired by Bridgewest.
Formex was founded in 2013 with Biotechnology Investment Group, a Bridgewest-backed firm that bought PharmaForm from the struggling Akela Pharma and spun it into a new company.